Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | KYNU | Q16719 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228613 | 1.00 | APAF1 (0.53) | APAF1LMNAMAPK1AOC3BCAT2 | |
| SCHEMBL7127998 | 1.00 | APAF1 (0.53) | APAF1LMNAMAPK1AOC3BCAT2 | |
| SCHEMBL25712023 | 0.83 | KYNU (0.68) | APAF1LMNAKDM4ERAB9AKYNU | |
| SCHEMBL23894335 | 0.82 | TRPA1 (0.57) | APAF1LMNAMAPK1AOC3CYP2D6 | |
| SCHEMBL12228632 | 0.82 | APAF1 (0.55) | APAF1LMNAMAPK1CYP2D6SRC | |
| Acetic Acid SCHEMBL18759625 | 0.81 | LMNA (0.58) | LMNAMAPK1AOC3BCAT2KDM4E | |
| SCHEMBL8935816 | 0.81 | APAF1 (0.50) | APAF1LMNAMAPK1CYP2D6SRC | |
| SCHEMBL5861277 | 0.80 | AOC3 (0.50) | AOC3KDM4EL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL2872818 | 0.80 | APAF1 (0.53) | APAF1LMNAMAPK1CYP2D6SRC | |
| SCHEMBL27564208 | 0.79 | LMNA (0.52) | LMNAMAPK1AOC3BCAT2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | APAF1 3189/4885LMNA 3632/4885MAPK1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.